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Peptides derived from the membrane proximal region of fusion proteins of human immunodeficiency viruses 1 and 2, Coronavirus 229 E, severe
acute respiratory syndrome coronavirus and Ebola virus were all potent antagonists of the formyl peptide receptor expressed in Chinese hamster ovary
cells. Binding of viral peptides was affected by the naturally occurring polymorphisms at residues 190 and 192, which are located at second extracellular
loop–transmembrane helix 5 interface. Substitution of R190 with W190 enhanced the affinity for a severe acute respiratory syndrome coronavirus
peptide 6 fold but reduced the affinity for N-formyl-Nle–Leu–Phe by 2.5 fold. A 12 mer peptide derived from coronavirus 229E (ETYIKPWWVWL)
was the most potent antagonist of the formyl peptide receptor W190 with a Ki of 230 nM. Fluorescently labeled ETYIKPWWVWL was effectively
internalized by all three variants with EC50 of ∼25 nM. An HKU-1 coronavirus peptide, MYVKWPWYVWL, was a potent antagonist but N-formyl-
MYVKWPWYVWLwas a potent agonist. ETYIKPWWVWL did not stimulate GTPγS binding but inhibited the stimulation by formyl-NleLeuPhe. It
also blockedβ arrestin translocation and receptor downregulation induced by formyl-Nle–Leu–Phe. This indicates that formyl peptide receptor may be
important in viral infections and that variations in its sequence among individuals may affect their likelihood of viral and bacterial infections.
© 2006 Elsevier B.V. All rights reserved.Keywords: Virus; Signal Transduction; G protein coupled receptor; Polymorphism1. Introduction
Neutrophils play an essential role in innate immunity. In ad-
dition to activating phagocytosis and secreting superoxides andAbbreviations: FPR, formyl peptide receptor; CHO S, Chinese hamster
ovary cells designed for suspension culture; HRSV, human respiratory syncytial
virus; FIV, feline immunodeficiency virus; fMLF, N-formyl-methionyl-leucyl-
phenylalanine; AIDS, Acquired Immunodeficiency Syndrome; SIV, Simian
Immunodeficiency Virus; HIV, human immunodeficiency virus; SARS, severe
acute respiratory syndrome; GP-41, 41 kilodalton glycoprotein; HR, Heptade
Repeat; FITC, Fluorescein isothiocyanate; formyl-Nle–Leu–Phe–Nle–Tyr–
Lys–FITC, formyl-Nle–Leu–Phe–Nle–Tyr–Lys labeled at the Lys residue with
Fluorescein isothiocyanate; formyl-Nle–Leu–Phe–Nle–Tyr–Lys–Alexa Fluor,
formyl-Nle–Leu–Phe–Nle–Tyr–Lys labeled at the Lys residue with Alexa
Fluor N-hydroxy-succinimide; ETYIK-(Alexa Fluor)WPWWVWL,
ETYIKWPWWVWL labeled with Alexa Fluor 488 N-hydroxy-succinimide;
GTPγS, guanosine 5′-3-O-(thio)triphosphate; TMH, transmembrane helix;
FPRL1, formyl peptide like receptor 1; FPRL2, formyl peptide receptor like 2
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doi:10.1016/j.bbadis.2006.05.008hydrolytic enzymes, the neutrophil must be able to chemotax, or
migrate toward the source of a chemoattractant. Upon activation
by a chemoattractant, G-protein coupled receptors on the mem-
brane of the neutrophil change conformation and bind to G pro-
teins, activating a signal transduction pathway that results in
intracellular actin polymerization, the formation of pseudopodia,
reorientation toward a chemoattractant gradient, and adhesion to
and infiltration through the blood vessel endothelium [1,2].
The formyl peptide receptor (FPR) is a chemoattractant G
protein-coupled receptor found on the surface of phagocytes. It is
thought to play an important role in allowing phagocytic cells to
recognize the presence of bacteria, which are believed to be the
source of formyl peptides [3]. FPR is activated by other ligands in
addition to fMLF. FPR binds peptides derived from the GP-41
envelope protein of HIV-1 [4,5]. FPR activation is inhibited by a
polypeptide secreted by S. aureus [6,7], an undecapeptide (Cy-
closporin H) derived from the fungus Tolypocladium inflatum [8],
and peptides derived from murine leukemia virus and human T
cell leukemia virus [9]. A peptide derived from herpes simplex
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neutrophils in a process that appeared to involve FPR [10]. Thus
FPR appears to interact with peptides derived from a variety of
sources.
Lentiviruses are associated with immunological impairment
in their respective hosts and both human immunodeficiency and
feline immunodeficiency viral infections increase the likelihood
of secondary bacterial infections [11]. Recently, Kubes et al.
[12] demonstrated that feline neutrophils exhibited a marked
(>90%) reduction of neutrophil chemotaxis toward fMLF fol-
lowing infection with FIV. It is possible that viral infections may
release factors which impair chemotaxis in vivo, which would
be consistent with the observations of virally derived peptides
on FPR.
Polymorphisms in the FPR appear to be very common. Saha-
gun-Ruiz et al. [13] did an extensive haplotype investigation of
FPR and reported finding at least 23 haplotypes for FPR. No
polymorphisms were found in the closely related receptor FPRL1
[13]. One possible reason for the existence of polymorphisms is
that polymorphisms might prevent pathogens from binding to
receptors and using them as an entry point into cells. Several G
protein-coupled receptors have been used by pathogens as a point
of entry into cells and the use of CCR5 andCXCR4 as co-receptors
for HIV-1 and CXCR4 as a co-receptor for FIVare notable exam-
ples [14–16]. The CCR5 receptor in African green monkeys [17]
has been shown to be polymorphic and these polymorphisms
provide some protection against SIV infection.
Numerous studies have indicated that patients with aggres-
sive periodontitis exhibit a ∼2 fold reduction in chemotaxis
toward fMLF [18–23]. Zhang et al. [24] found that aggressive
periodontitis patients of African American decent were more
likely (P=0.002) to have at least one allele as the R190/K192
polymorphism when compared to African American controls
(R/W190 and N/K192 are located at the extracellular loop 2–
TMH5 interface). They also found that aggressive periodontitis
patients of African American decent were much less likely
(P=0.003) to have one of their alleles as the W190/N192 poly-
morphism. R190/K192 was not associated with an increased risk
of aggressive periodontitis among either Brazilians or Turks nor
was W190/N192 associated with reduced incidence of aggres-
sive periodontal disease in these two populations [24]. It is
unclear at this point why FPRW190/R190 and N192/K192 are
only associated with altered risk of aggressive periodontitis in
African Americans but the effects of these polymorphisms on
receptor function clearly needs to be determined.
We previously observed that a single amino acid mutation,
D106N in TMH3, markedly enhanced the ability of FPR to bind a
peptide derived from HIV-1 gp41 but also markedly reduced its
affinity for fMLF [25]. Thus, determination of the affinity of these
two very different ligands provides a way to observe changes in
ligand specificity associated with changes in FPR. In order to
determine whether polymorphisms W190 or K192 might simi-
larly affect ligand binding and possibly explain why K192 is
associatedwith an increased risk of periodontal disease andW190
is associated with reduced risk of disease, we expressed R190/
N192,W190/N192, and R190/N192 FPR variants in CHOS cells
and determined their affinity for numerous ligands, includingseveral formyl peptides and peptides derived from HIV-1 gp-41
and analogous peptides derived from HIV-2, SARS coronavirus,
coronavirus 229E, coronavirus OC43, and Ebola virus.
2. Materials and methods
2.1. Cell transfection
Geneticin- and ampicillin-resistant and FPR-expressingDNA plasmid PBGSA
was prepared as previously described [26]. Mutagenesis was performed according
to the Quickchange Mutagenesis Kit instructions using pfu DNA polymerase
essentially as described previously [27]. The plasmids were cut with BspEI and
XboI and ligated back into the original FPR-expressing DNA plasmid PBGSA.
This step was necessary to obtain good expression levels. DNA was purified,
sequenced (Davis Sequencing) and transfected into CHO S cells (Invitrogen) using
Lipofectamine 2000, cloned, and maintained in Gibco CHO-S-SFMII media
containing 100 μg/ml G418. Numerous clones expressing R190/N192, R190/
K192, or W190/N192 were evaluated for their expression by FACScan analysis
using 10 nM formyl-Nle–Leu–Phe–Nle–Tyr–Lys–FITC . A clonewas chosen for
each sequence that exhibited nearly identical levels of surface expression; less than
∼20% difference between the three variants.
2.2. Peptide synthesis
Peptides were obtained from either Genscript or Macromolecular Resources
and purified by reverse phaseHPLC. Peptideswere synthesizedwith unmodifiedN
and C termini. Mass spectral data was provided with each peptide and the major
mass peak matched the expected mass of the peptide in all cases. Formyl-Nle–
Leu–Phe was obtained from Sigma and used without further purification.
2.3. Fluorescent labeling of peptides and anti β-arrestin antibody
Peptides were reacted with Alexa Fluor 488 n-hydroxysuccinimidylester
(Molecular Probes) at a 1.5 to 1 mole ratio (peptide to fluorophore) in DMSO/1%
triethylamine at 30 °C for∼4 h and purified by reversed phase HPLC. For formyl-
Nle–Leu–Phe–Nle–Tyr–Lys the only site of labeling is the Lys. For
ETYIKWPWWVWL either the Lys could be labeled or the N-terminus could be
labeled. However, the intrinsic reactivity of the ε amino of Lys is generally ∼100
fold greater than the N-terminal amino group so it is likely that almost all labeling
occurs at the lys when the peptide is used in excess to the fluorophore. Anti β-
arrestin antibody (BD Transduction Laboratories) at 250 μg/ml in PBS was
incubated with 5 mM 6-(fluorescein-5-carboxamido)hexanoic acid, succinimidyl
ester (Molecular Probes) for 1 h at 37 °C and the labeled antibody was purified by
HPLC gel filtration on a Sigmachrome 100 column. The antibody contained
approximately 1.5 moles of fluorescein/mole of antibody.
2.4. Determination of GTPγS binding
Membranes from CHO S cells expressing FPR were prepared as follows: The
cells were centrifuged at 100 g for 5 min. The cell pellets were resuspended in
10 mM phosphate, pH 7.4, 10 mMKCl, 100 mMNaCl, 0.1 μMGDP and 5 μg/ml
leupeptin. The cells were sonicated for 30 s at 20% power and stored as aliquots of
equal amounts of protein at −70 °C. Binding assays were done in 0.2 ml of 10 mM
HEPESpH7.4, 100mMNaCl, 1mMMg++, 1μMGDP. Samples containing 30μg
of protein were preincubated with ligand at 30 °C for 10 min, 0.05 μCi of [35S]
GTPγSwas added and the reaction continued for 10min. The sampleswere filtered
through a GF/C glass microfiber filter. Filters were washed with 15 ml of 10 mM
phosphate, pH 7.4, 3 mM KCl, 100 mM NaCl , and the bound [35S] GTPγS was
determined by liquid scintillation counting.
2.5. FACScan analysis of ligand binding to FPR variants expressed in
CHO S cells
CHO S cells (100 μl in Gibco CHO-S-SFMII) were added to 3 mM KCl,
100 mM NaCl, 10 mM sodium phosphate, pH 7.4, 1 mM Mg++, 1 mM Ca++
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concentrations of fluorescent peptide. The mean fluorescence of the cells was
determined, and the mean fluorescence observed in non-expressing CHO S cells
(non-specific binding) was subtracted. The data were then analyzed by nonlinear
least squares analysis and theKd andBmax determined. The affinity of peptides was
determined using increasing concentrations of peptide in the presence of constant
formyl-Nle–Leu–Phe–Nle–Tyr–Lys–FITC. The Ki was then determined by non-
linear least squares analysis using the known Kd for formyl-Nle–Leu–Phe–Nle–
Tyr–Lys–FITC for each FPR variant and the observed EC50 of each peptide.
Formyl-Nle–Leu–Phe–Nle–Tyr–Lys–FITC concentrations of 0.3 nM, were used
for all three FPR variants, and theKi was determined from the equationKi=EC50/
(1+(ligand/Kd) using the graphics/statistics program Graphpad Prizm.
2.6. Translocation of arrestin
CHO S cells were incubated in Gibco CHO-S-SFMII at 37 °C for 1 h with
10μMfNle–Leu–Phe, 10μMETYIKWPWWVWL, 10μMeachof both peptides
or no peptides. DMSO was the same concentration in all cases. The cells were
washed with 10 ml 10 mM phosphate, pH 7.4, 3 mM KCl, 100 mM NaCl. Cells
were resuspended in 10mMphosphate, pH 7.4, 3 mMKCl, 100mMNaCl , 0.02%
saponin, 60 μg/ml leupeptin, protein phosphatase inhibitors (Sigma) 1/100, and
8 nM of fluorescein labeled anti arrestin. The cells were incubated for 15 h at 4 °C,
diluted 1 to 3 with 10 mM phosphate, pH 7.4, 3 mMKCl, 100 mMNaCl, and then
analyzed by FACScan. Background was determined by adding unlabeled anti-
arrestin in 10 fold molar excess to the fluorescein labeled anti arrestin.
2.7. Downregulation of surface FPR
CHO S cells expressing FPR were incubated in Gibco CHO-S-SFMII at 37 °C
for 1 h with 10 μM fNle–Leu–Phe, 10 μM ETYIKWPWWVWL, 10 μM each of
both peptides or no peptides. DMSO was the same concentration in all cases. The
cells were washed 2× with 10 ml 10 mM phosphate, pH 7.4, 3 mM KCl, 100 mM
NaCl at 4 °C. The cells were resuspended in 100 mM NaCl, 3 mM KCl, 10 mM
sodium phosphate, pH 7.4, 1 mM Mg++, 1 mM Ca++, 5% fetal bovine serum and
50 nM formyl-Nle–Leu–Phe–Nle–Tyr–Lys–FITC and incubated for 1 h at 4 °C
and analyzed by FACScan as describe above. Background observed with non-
expressing CHO S cells was subtracted.
2.8. Internalization of ETYIK-(Alexa Fluor)WPWWVWL
CHO S cells expressing FPR were incubated in Gibco CHO-S-SFMII at 37 °C
for 1 h with varying concentrations ETYIK-(Alexa Fluor)WPWWVWL, The cells
were washed 2× with 10 ml 10 mM phosphate, pH 7.4, 3 mMKCl, 100 mMNaCl
at 4 °C. The cells were resuspended in 100 mMNaCl, 3 mMKCl, 10 mM sodium
phosphate, pH 7.4, 1 mM Mg++, 1 mM Ca++, 5% fetal bovine serum and 10 μM
formyl-Nle–Leu–Phe and incubated for 1 h at 4 °C to displace any ligand bound to
surface receptor. Internalized ligand was determined by FACScan as describe
above. Background observed with non-expressing CHO S cells (<20% observed
with expressing cells) was subtracted.
2.9. Statistical analysis
Experimental results are expressed as the mean±standard error of the mean.
The significance was evaluated by unpaired t test (2 tailed) using the computer
program Graphpad Prizm.Table 1








ZAIRE EBOLA SPIKE PROTEIN3. Results
3.1. Choice of viral peptides for analysis
Peptides derived from HIV-1 GP-41 have previously been
shown to interact with FPR [4] and we previously observed that a
gp41 36mer (T20/DP178) inhibited formyl-Nle–Leu–Phe–Nle–
Tyr–Lys–FITC binding to FPR [25]. Since gp41 is a fusion
glycoprotein which contains two heptad repeat regions, we chose
viral glycoproteins with this property. T20/DP178 is derived from
the second heptad repeat region of HIV-1 gp41 but also includes
residues C-terminal to the end of the heptad 2 repeat region [28].
Sainz et al. called these residues in HIV-1 and SARS coronavirus
the “aromatic rich region” and they noted a similar region in Ebola
virus [29]. This region has also been called the membrane pro-
ximal region. We therefore chose to synthesize peptides from
HIV-2 and several human coronaviruses (SARS, OC43, and
229E) that corresponded to T20/DP178 in HIV-1. An alignment
of sequences is shown in Table 1, which also includes the newly
discovered coronaviruses HKU-1 and NL-63 [30–32] and the
aromatic rich region from the Ebola spike protein.
The alignments show that all these viral sequences contain
aromatic rich C-termini which are very rich in tryptophan. The 12
C-terminal residues of the coronaviruses are highly conserved. The
12 c-terminal residues of HIV-1 T20/DP178 are also highly con-
served among known HIV-1 sequences and this 12 amino acid
region overlaps the epitopes of 2 broadly protective anti-HIV
antibodies 2F5 and 4E10 [33,34].12mer peptides corresponding to
C-termini of the sequences for HIV-1, HIV-2, SARS coronavirus,
and coronavirus 229Ewere synthesized (residues are underlined in
Table 1) as well as a 12 residue peptide corresponding to the
aromatic rich region from the Ebola spike protein. We also syn-
thesized smaller peptides of coronavirus 229E to localize residues
which might be important in binding (ETYIKWP, WPWWVWL,
and WWVWL).
3.2. Ligand specificity and affinity determination of
R190/N192, W190/N192, and R190/K192 variants
We transformed CHO S cells with FPR variants R190/N192,
W190/N192, and R190/K192. A schematic figure showing the
topology of FPR is shown in Fig. 1. The location of R/W 190
and N/K 192 at the extracellular loop 2–TMH5 interface is
indicated in the figure. Residues that have been shown in
previous crosslinking and mutagenesis studies to be important
in ligand binding are V83 (TMH2), R84 (TMH2), K85 (TMH2)








Fig. 1. Transmembrane model of FPR. Residues in black are residues that have been shown in previous crosslinking and mutagenesis studies to be important in ligand
binding [25,26,35]. Residues in gray are sites of known polymorphisms [13].**R or W, *N or K.
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W254A (TMH6), Y257A (TMH6) and F291A (TMH7) [26].
D106 and R201 are the sites of formyl group binding and R205
interacts with the C-terminus of fMLF [25]. The beginning of
TMH5 was assigned to residue 191 and the end to residue 228
by hydrophobicity analysis according to Kyte and Doolittle
[36]. We analyzed CHO S cells expressing R190/N192, W190/
N192, and R190/K192 FPR for their ability to bind formyl-
Nle–Leu–Phe–Nle–Tyr–Lys–FITC. We observed that the po-
lymorphisms in FPR result in significantly altered formyl-Nle–
Leu–Phe–Nle–Tyr–Lys–FITC binding affinity (Fig. 2) with
R190/K192 having the highest affinity (Kd=0.71±0.10 nM),
R190/N192 intermediate (Kd=1.06±0.09 nM), and W190/
N192 having the lowest affinity (Kd=1.68±0.13 nM); P=0.02;
R190/N192 vs. R190/K192 : P=0.001; R190/N192 vs. W190/
N192, and P<0.0001 R190/K192 vs. W190/N192, respective-
ly). We also synthesized formyl-Nle–Leu–Phe–Nle–Tyr–Lys–
Alexa Fluor and determined the Kds: R190/K192 (Kd=0.76±
0.05 nM), R190/N192 (Kd=1.20±0.14 nM), and W190/N192
(Kd=2.0±0.10 nM), the results being essentially identical as
that observed with formyl-Nle–Leu–Phe–Nle–Tyr–Lys–FITC.We then determined the affinities of a broad range of peptides
for these three polymorphisms based on their ability to compete
with formyl-Nle–Leu–Phe–Nle–Tyr–Lys–FITC (Table 2).
We observed that R190/K192 exhibited the highest affinity for
formyl-Nle–Leu–Phe (chosen over fMLF in order to prevent
possible oxidation of methionine) and MMWLL, a potent non-
formylated chemoattract for FPR, [25,37]. Both formyl-Nle–
Leu–Phe and MMWLL bound with ∼3 fold higher affinities to
R190/K192 than to W190/N192. W190/N192 had the highest
affinity for most virally derived peptides, especially the corona-
virus peptides. W190/N192 bound the SARS coronavirus pep-
tides with 4–6 fold higher affinity than either R190/N192 or
R190/K192. This indicates that changes in these two positions
affected ligand specificity, but most of the change in specificity
was associated with the R toW change at residue 190.Most of the
binding affinity of the coronavirus 229E peptides appears to
reside in the 5 C-terminal residues sinceWWVWL exhibited only
a modest reduction in affinity compared to ETYIKWPWWVWL.
ETYIKWPwas completely devoid of activity. WPWWVWL had
similar affinity to WWVWL. ETYIKWPWWVWL bound to all
three FPR variants with 15 to 30 fold higher affinity than the
Fig. 2. Determination of affinity of ligand binding. Binding of formyl-Nle–Leu–
Phe–Nle–Tyr–Lys–FITC to FPR variants R190/N192, R190/K192, or W190/
N192 was determined as a function of ligand concentration.
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coronavirus peptides over HIV-2 peptides. The reverse peptide,
LWVWWPWKIYTE, exhibited very little inhibition at con-
centrations up to 40,000 nM. Formylation of MYVKWP-
WYVWL enhanced its affinity 6 fold for both R190/N192 and
R190/K192 but had only a very modest 2 fold affect on affinity
for W190/N192.
In order to determine whether the binding of coronavirus
peptides was specific for FPR, we labeled ETYIKWPWWVWL
with Alexa Fluor 488, purified it by HPLC, and compared the
binding to CHO S cells expressing R190/N192, W190/N192,
R190/K192 or cells not expressing FPR. All three FPR variants
exhibited binding of this Alexa Fluor 488 labeled peptide, com-
pared with non-expressing cells (Fig. 3). W190/N192 exhibited
the greatest binding at saturation, but the Kds for R190/N192,
R190/K192, and W190/N192 were similar: 121±18 nM, 115±
10 nM, and 99±10 nM, respectively. When ETYIK-(Alexa
Fluor)WPWWVWL and formyl-Nle–Leu–Phe–Nle–Tyr–Lys–
Alexa Fluor binding to R190/N192, R190/K192, and W190/
N192 were determined at saturating concentrations of either li-
gand, Alexa Fluor- ETYIKWPWWVWL exhibited twice the
fluorescence of formyl-Nle–Leu–Phe–Nle–Tyr–Lys–Alexa
Fluor when bound to W190/N192, but only about 60% the fluo-
rescence of formyl-Nle–Leu–Phe–Nle–Tyr–Lys–Alexa Fluor
bound to either R190/N192 or R190/K192 (data not shown, but
see below for an explanation).
We also investigated the ability of ETYIK-(Alexa Fluor)WPW-
WVWL to be internalized at 37 °C. The results are shown in Fig. 4.
The EC50s for internalization were ∼4 fold lower than the Kd for
binding (R190/N192, R190/K192, and W190/N192; 29±5 nM,
27±8 nM, and 20±3 nM, respectively). This indicates that either
the affinity of ETYIK-(Alexa Fluor)WPWWVWL for FPR is
greater at 37 °C used for internalization than at 4 °C used in the
binding experiments to prevent internalization or that saturation of
the internalization process occurs at concentrations well belowthose required for receptor saturation. Since the peptides behaved
as antagonists, we were somewhat surprised that they were so
readily internalized. This probably reflects turnover of FPR on the
cell surface, since treatment of the cells with ETYIKWPWWVWL
did not result in net receptor down regulation (see Fig. 9) below.
Nonetheless, it indicates that if a virus interacts with FPR, it could
be effectively internalized even if it is unable to activate the
receptor.
We also quantitated formyl-Nle–Leu–Phe–Nle–Tyr–Lys–
Alexa Fluor internalization in R190/N192, R190/K192, and
W190/N192, by fluorescence spectroscopy in the absence or pre-
sence of 0.1% SDS to correct for any quantum yield change in
Alexa Fluor fluorescence which might occur upon binding to FPR.
Interestingly, formyl-Nle–Leu–Phe–Nle–Tyr–Lys–Alexa Fluor
fluorescence internalized by W190/N192 FPR was enhanced in
the presence of 0.1% SDS by 95±5%, but 0.1% SDS did not affect
the fluorescence of formyl-Nle–Leu–Phe–Nle–Tyr–Lys–Alexa
Fluor internalized by either R190/N192 FPR or R190/K192 FPR.
This indicates that W190 quenches the fluorescence of formyl-
Nle–Leu–Phe–Nle–Tyr–Lys–Alexa Fluor by ∼50% when it is
bound to the receptor and thus must be sufficiently near the Alexa
Fluor moiety of formyl-Nle–Leu–Phe–Nle–Tyr–Lys–Alexa
Fluor when the peptide is bound to W190/N192 FPR so that
W190 can contact AlexFluor during the excited state [38]. This
indicates that W190 resides in or very close to the ligand binding
pocket (∼1 to 1.5 nm average distance [38]). Since Alexa Fluor-
ETYIKWPWWVWL exhibited twice the fluorescence of formyl-
Nle–Leu–Phe–Nle–Tyr–Lys–Alexa Fluor when bound to W190/
N192 (the expected value if it was not quenched), it is unlikely that
W190 can come in contact with the Alexa Fluor of ETYIK-(Alexa
Fluor)WPWWVW when bound to FPR. After correcting for the
quenching of formyl-Nle–Leu–Phe–Nle–Tyr–Lys–Alexa Fluor
on W190/N192, we estimate that ETYIK-(Alexa Fluor)WPW-
WVW is internalized at about 20–30% of the rate of formyl-Nle–
Leu–Phe–Nle–Tyr–Lys–Alexa Fluor in R190/N192, R190/K192,
and W190/N192, based on their relative internalization rates by
FACScan. This level of internalization was too low to accurately
quantitate by direct fluorescence readings so the degree of quench-
ing of Alexa Fluor- ETYIKWPWWVWL could only be estimated
by FACScan analysis.
We tested several peptides including formyl-Nle–Leu–Phe,
ETYIKWPWWVWL, MYVKWPWYVWL and formyl-MYV-
KWPWYVWL for their ability to stimulate GTPγS binding. Both
300 nM formyl-Nle–Leu–Phe and 300 nM formyl-MYVKWP-
WYVWL stimulated GTPγS binding in all three FPR variants, but
neither ETYIKWPWWVWL nor MYVKWPWYVWL had any
effect on the three FPR variants (Fig. 5). This indicated that the
formyl group on formyl- MYVKWPWYVWL was essential for
agonist activity but not for binding. 2 μM MYVKWPWYVWL
inhibited 300 nM formyl-MYVKWPWYVWL stimulation of
GTPγS binding by W190/N192 FPR by 60% but did not have a
significant effect on formyl-MYVKWPWYVWL stimulation of
GTPγS binding in either R190/N192 FPR or R190/K192 FPR.
This is consistent with the data in Table 2 where formylation of
MYVKWPWYVWL enhanced the affinity for R190/N192 and
R190/K192 by 6 fold but only 2 fold for W190/N192. We then
tested ETYIKWPWWVWL for its ability to inhibit the stimulation
Table 2
Ki (nM±SEM) for binding of peptides to R190/N192, R190/K192, or W190/N192 FPR
R190/N192 R190/K192 W190/N192
Formyl-NleLeuPhe 67±16 62±8 160±25 ⁎⁎
MMWLL 330±50 190±30 840±200 ⁎
HKU coronavirus peptides
MYVKWPWYVWL 783±50 837±32 263±9 ⁎⁎
Formyl-MYVKWPWYVWL 134±9 134±12 133±8
SARS coronavirus peptides
36mer 3,270±250 3,140±150 770±25 ⁎⁎
12 mer (EQYIKWPWYVWL) 2,050±107 2,400±170 390±30 ⁎⁎
Coronavirus OC43 peptide
36mer 850±80 740±80 460±50 ⁎⁎
Coronavirus 229E peptides
36 mer 10,000±1400 6,800±670 1300±60 ⁎⁎
12 mer (ETYIKWPWWVWL) 533±30 370±30 270±10 ⁎⁎
LWVWWPWKIYTE (reverse) >50,000 >50,000 >50,000
WPWWVWL ∼600 ∼600 ∼600
WWVWL ∼1000 ∼1400 ∼600
ETYIKWP >260,000 >260,000 >260,000
HIV-1 peptides
36 mer 1500±80 820±50 960±200
12 mer (ELDKWASLWNWF) 1200±100 940±150 1050±100
HIV-2 peptides
37 mer 15,700±1000 10,000±1200 4000±1000 ⁎⁎
12 mer (KLNSWDVFGNWF) 15,000±2000 9,500±2000 4700±290 ⁎⁎
Ebola peptide
12 mer (NDNWWTGWRQWI) 1400±200 1200±90 1200±150
⁎ P<0.05 W190/N192 vs. either R190/N192 or R190/K192.
⁎⁎ P<0.01 W190/N192 vs. either R190/N192 or R190/K192.
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KWPWWVWLwas more effective in inhibiting the stimulation of
GTPγS binding in W190/N192 (EC50=300±120 nM; (P=0.003
vs. R190/K192;P=0.005 vs. R190/N192)) than either R190/N192
(EC50=1600±400 nM) or R190/K192 (EC50=1600±440 nM).
These results are consistent with the results in Table 2, which show
that W190/N192 has a similar affinity for formyl-Nle–Leu–Phe
and ETYIKWPWWVWL but that R190/N192 and R190/K192
have 6–8 fold higher affinities for formyl-Nle–Leu–Phe than ET-
YIKWPWWVWL. We also tested ETYIKWP and WWVWL for
their ability to inhibit the stimulation of GTPγS binding by 300 nM
formyl-Nle–Leu–Phe in W190/N192 FPR. The results are shown
in Fig. 7.WWVWL inhibited formyl-Nle–Leu–Phe stimulation of
GTPγS bindingwith a slightly higher EC50 (EC50=1300 nM) than
ETYIKWPWWVWL (EC50=300±120 nM). ETYIKWP had no
effect. Again this is consistent with the results shown in Table 2.We
also tested the HIV-1 36 mer and the Ebola virus 12 mer for their
effects on GTPγS binding. As observed with ETYIKWPWWV-
WL, neither peptide at 10 μM stimulated GTPγS binding but both
peptides at 10 μM markedly inhibited the stimulation by 300 nM
formyl-Nle–Leu–Phe (data not shown).
Previous studies with other G protein coupled receptors have
indicated that some ligands that fail to activate G proteins are
nonetheless able to promote β-arrestin translocation and activateβ-arrestin dependent signaling pathways [39–42]. Therefore, we
also tested R190/N192, W190/N192, and R190/K192 expressing
CHO S cells for the ability to undergo β-arrestin translocation in
response to 10 μM formyl-Nle–Leu–Phe, 10 μM ETYIKWP-
WWVWL, or 10 μM each of both peptides (Fig. 8). Formyl-Nle–
Leu–Phe caused β-arrestin translocation in CHO S cells expres-
sing R190/N192, R190/K192, andW190/N192 but not in CHO S
cells not expressing FPR. ETYIKWPWWVWL did not cause
translocation in CHO S cells expressing R190/N192, W190/
N192, or R190/K192 FPR. ETYIKWPWWVWL inhibited trans-
location in response to formyl-Nle–Leu–Phe by 18±4% in R190/
N192 FPR expressing cells, 20±9% in R190/K192 FPR expres-
sing cells, and 77±10% inW190/N192 FPR expressing cells (P<
0.006; W190/N192 vs. either R190/N192 or R190/K192). Again
ETYIKWPWWVWL was more effective against W190/N192
than with R190/N192 or R190/K192, but it exhibited only anta-
gonist activity in this assay.
Finally, we tested R190N192, R190/K192, and W190/N192
expressing CHO S cells to undergo surface receptor downregu-
lation in response to 10 μM formyl-Nle–Leu–Phe, 10 μM
ETYIKWPWWVWL, or 10 μM each of both peptides (Fig. 9).
Formyl-Nle–Leu–Phe caused receptor down regulation in CHO
S cells expressing R190/N192, R190/K192, orW190/N192 FPR
variants; 76±1.2%, 85±0.4%, and 76±3%, respectively.
Fig. 3. Determination of affinity of Alexa Fluor labeled ETYIKWPWWVWL.
Binding of Alexa Fluor labeled ETYIKWPWWVWL to W190/N192 FPR,
R190/K192 FPR, and R190/N192 FPR and to CHO-S cells not expressing FPR
are shown as a function of concentration. Kds for W190/N192, R190/K192, and
R190/N192 were 99±10 nM, 115±10 nM, and 121±18 nM, respectively.
Fig. 5. Stimulation of GTPγS binding by formyl-Nle–Leu–Phe, formyl-
MYVKWPWYVWL, MYVKWPWYVWL or ETYIKWPWWVWL in cells
expressing W190/N192, R190/K192, or R190/N192 FPR.
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regulation in CHO S cells expressing R190/N192, R190/K192,
or W190/N192 FPR. ETYIKWPWWVWL inhibited receptor
downregulation in response to formyl-Nle–Leu–Phe by 16±2%
in R190/N192 FPR expressing cells, 20±2% in R190/K192 FPR
expressing cells, and 64±6% in W190/N192 FPR expressing
cells (P<0.001 for W190/N192 vs. either R190/N192 or R190/
K192). As with the previous experiments, ETYIKWPWWVWL
was more effective against W190/N192 than R190/N192 or
R190/K192. The effects on downregulation closely correlatedFig. 4. ETYIKWPWWVWL labeled with Alexa Fluor 488 is internalized in CHO
cells expressing FPR. CHO cells expressing FPRW190/N192, FPRR190/N192 or
FPR R190/ K192 were incubated with indicated concentrations of Alexa Fluor
labeled peptide for 37 °C for 1 h and the amount of internalized ligand was
determined. The very low internalization of CHO cells not expressing FPR has
been subtracted.
Fig. 6. Inhibition of stimulation of GTPγS binding induced by formyl-Nle–
Leu–Phe by ETYIKWPWWVWL in FPR variants R190/N192, R190/K192, or
W190/N192. Inhibition of FPR activation by viral peptides. Inhibition of
stimulation of GTPγS binding induced by formyl-Nle–Leu–Phe by
ETYIKWPWWVWL. ETYIKWP, or WWVWL in W190/N192 FPR.
Fig. 8. Arrestin translocation in the presence of various FPR ligands. Relative
arrestin translocationwas determined in non-expressingCHOcells, R190/N192FPR
expressing cells, R190/K192 FPR expressing cells, or W190/N192 FPR expressing
cells in response to 10 μM formyl-Nle–Leu–Phe, 10 μM ETYIKWPWWVWL, or
10 μM formyl-Nle–Leu–Phe + 10 μM ETYIKWPWWVWL. 10 μM
ETYIKWPWWVWL inhibited translocation in response to 10 μM formyl-Nle–
Leu–Phe by 18±4% in R190/N192 FPR expressing cells, 20±9% in R190/K192
FPR expressing cells, and 77±10% in W190/N192 expressing cells (P<0.006 for
W190/N192 FPR vs. either R190/N192 or R190/K192).
Fig. 7. Inhibition of FPR activation by viral peptides. Inhibition of stimulation of
GTPγS binding induced by formyl-Nle–Leu–Phe by ETYIKWPWWVWL.
ETYIKWP, or WWVWL in W190/N192 FPR.
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given association between β-arrestin translocation and down-
regulation [43].
4. Discussion
R190/K192 exhibited the highest affinity for formyl-Nle–Leu–
Phe, formyl-Nle–Leu–Phe–Nle–Tyr–Lys–FITC, and formyl-
MYVKWPWYVWL, which indicates that it is not defective in
binding formyl peptides. African American patients expressing the
R190/K192 polymorphism were associated with increased risk of
aggressive periodontitis whereas those expressing the W190/N192
polymorphism were associated with reduced risk [24]. Our data
clearly show no evidence that R190/K192 is defective and we find
that W190/N192 exhibited a 2.6 fold lower affinity for formyl
peptides than R190/K192. Zhang et al. also reported that R190/
K192 was not associated with an increased risk of aggressive
periodontitis among either Brazilians or Turks nor was W190/
N192 associated with reduced incidence of aggressive periodontal
disease in these two populations [24] so it was unclear why this
association was only true for African Americans. A recent study by
Maney et al. [44] was unable to confirm the association of aggres-
sive periodontitis with R190/K192 in African Americans, but did
find an association with a silent polymorphism I116I. Our data
finding no defect in R190/K192 are consistent with the study of
Maney et al. [44] and also with the observation that R190/K192
was not associated with increased risk for aggressive periodontitis
in either Turks or Brazilians.
In Fig. 1, we show the relative positions of R/W 190 and N/K
192 at the extracellular loop 2-TMH5 interface to other residues in
FPR which we previously identified as important in ligand bind-
ing [25,26,35]. We previously determined that D106 and R201likely form an ion pair between TMH3 and TMH5 and that this
ion pair imparts formyl group selectivity to ligand binding since
mutation of either residue changes the preference of formylated to
non-formylated peptide from 4000/1 to ∼1/3 and 1/1, respec-
tively, for D106N and R201A [25]. Here we observe thatW190 is
likely to be close to the lys residue of formyl-Nle–Leu–Phe–Nle–
Tyr–Lys–Alexa Fluor since quenching of the Alexa Fluor fluo-
rophore is observed only in W190/N192 and not in either R190/
N192 or R190/K192. It is likely therefore that when bound,
formyl-Nle–Leu–Phe–Nle–Tyr–Lys–Alexa Fluor is in a some-
what helical conformation (it contains residues with high helical
propensity) with the formyl group near R201 and the AlexFluor
moiety nearW190 and presumably near R190 as well. This mode
of binding is different from that proposed for fMLF where the C-
terminus of fMLF interactswithR205 [25]. This is consistentwith
our previous observations that mutation of R205 to A results in a
1000 fold reduction of affinity to fMLF [25] but only an 8 fold
reduction in affinity for formyl-Nle–Leu–Phe–Nle–Tyr–Lys–
FITC [26]. Given that W190/N192 binds coronaviral peptides
Fig. 9. Down regulation of FPR surface expression in response to various ligands.
Surface expression of FPR in W190/N192 FPR expressing cells, R190/K192 FPR
expressing cells, or R190/N192 FPR expressing cells was determined after expo-
sure for 1 h at 37° to either 10 μM formyl-Nle–Leu–Phe, 10 μM ETYIKWP-
WWVWL, or 10 μM formyl-Nle–Leu–Phe+10 μM ETYIKWPWWVWL.
ETYIKWPWWVWL inhibited receptor downregulation in response to formyl-
Nle–Leu–Phe by 16±2% in R190/N192 FPR expressing cells, 20±2% in R190/
K192 FPR expressing cells, and 64±6% in W190/N192 FPR expressing cells.
(P<0.001 W190/N192 vs. either R190/N192 or R190/K192).
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interacts with some as yet unidentified residues in these peptides.
One explanation of why R190/K192 binds formyl peptides better
than W190/N192 is that the former contains two additional posi-
tive charges. Formylation removes the positive charge from the
N-terminus of peptides. If R190 is near the entry site of the ligand,
the positive charge would repel peptides with free N-termini but
allow entry of formylated ones. Since formyl-Nle–Leu–Phe has a
net negative charge, it would be attracted toward R190 but not
W190. W190 would be expected to exhibit a relative preference
for peptides with free N-termini and peptides with net positive
charges compared to R190. This is consistent with our obser-
vation that MYVKWPWYVWL exhibits a 3 fold higher affinity
for W190/N192 than for R190/N192 or R190/K192 and that
formylation of MYVKWPWYVWL enhances its affinity 6 fold
with R190/N192 and R190/K192 but only 2 fold with W190/
N192. Formyl-MYVKWPWYVWLhas a net charge of zero, and
it binds equally well to all three variants.
Su et al. [4] originally observed that DP178/T-20, a peptide
derived from the C-terminal HR and membrane proximal region
of gp41 of human immunodeficiency virus type 1 (HIV-1), elic-ited chemotaxis in neutrophils and monocytes. They determined
that this chemotaxis was a result of its ability to bind to and
activate FPR. Su et al. [4] also observed that shorter versions of
DP-178 acted as antagonists of FPR. We subsequently showed
that DP178 binds to FPR expressed in CHO S cells and observed
that two FPR mutants (D106N and R201A), which bind fMLF
poorly, exhibited an enhanced ability (30 fold and 3 fold, respec-
tively) to bind DP178/T20 [25]. Here we observed that R190/
N192, W190/N192, and R190/N192 FPR variants all exhibited
similar affinities for DP178/T20 and that DP178/T20 behaved as
an antagonist based upon its inability to stimulate GTPγS binding
and its ability to inhibit the stimulation of GTPγS by formyl-Nle–
Leu–Phe.
HR regions appear to be a common motif in many viral fusion
proteins [45]. They exist as sequential helical domains; one n
terminal HR region (HR1) adjacent to the fusion peptide and a c-
terminal HR region (HR2) close to the transmembrane anchor.
Peptides derived from the HR2 and proximal membrane regions of
HIV-1, SIV, HRSV, human parainfluenza virus type 3, measles
virus, and a coronavirus have all been shown to be able to block
virus infection [28,46–48]. A twelve mer peptide derived from the
proximal membrane region of FIV gp41, QLQKWEDWVRWI,
was a potent (low nanomolar) inhibiter of FIV infection [49]. Here
we observed that peptides derived from the proximal membrane
region of HIV-1, HIV-2, Ebola virus, SARS coronavirus, and
coronavirus 229E act as antagonists to the formyl peptide receptor.
The coronavirus peptides are the most potent antagonists and these
peptides exhibited an enhanced affinity for W190/N192 FPR. Our
observation that tryptophan-rich peptides act as antagonists is
consistent with the observation of Bae et al., who observed that
WRWWWW was a potent antagonist for FPRL1 and FPRL2
[50,51]. WRWWWW did not affect FPR [50], and it has been
shown that DP178/T20 does not bind to FPRL1 [4], indicating that
these receptors have slightly different ligand binding specificities
but that both receptors may bind tryptophan rich peptides. A
recently discovered FPRL2 agonist is also tryptophan rich [52] and
the C-terminus of that peptide,WPWQVL, is remarkably similar to
WPWWVWL which we found to be a potent antagonist for FPR.
The FPRL2 agonist did not, however, bind to or activate FPR.
Coronaviruses are common infections among the human po-
pulation [53,54] and as such might affect the evolution of FPR if
they were able to attach to FPR, become internalized, and spread
through the body on the many cells that express FPR [55]. On the
other hand, it is possible that FPR's ability to bind virally derived
peptides allows it in someway to recognize the presence of a viral
infection and inhibit its spread. A recent report showed that HIV-1
viruses are inactivated by transport to acidic endosomes and
proteosomes and that blocking these processes can increase HIV-
1 infectivity by up to 400 fold [56]. If FPR could bind viruses and
transport them to endosomes and proteosomes, thismight result in
protection against viral infection. Another possibility is that FPR
could serve as a “fly-trap” for viruses and prevent them from
finding their appropriate receptor. Also, FPR might interact with
the aromatic rich region subsequent to virus binding to a surface
receptor and prevent membrane fusion. The scenarios are not of
coursemutually exclusive and the binding of viruses to FPR could
have positive or negative consequences depending on the exact
702 J.S. Mills / Biochimica et Biophysica Acta 1762 (2006) 693–703situation. Klestadt et al. [57] observed that activation of FPR in
THP-1 cells markedly downregulated the expression of CD4 and
CD13, the receptors for HIV-1/HIV-2 and coronavirus 229E,
respectively [11,58,59]. In addition, activation of FPR downregu-
lates the expression of CCR5 and CXCR4 [60], the co-receptors
of HIV-1 and HIV-2 [9,58]. Thus activation of FPR could serve as
protection against viral infection by downregulation of viral re-
ceptors, and presumably FPR antagonists would prevent down-
regulation. Ueda et al. noted that the HIV-1 envelope gp41 was
able to down regulate the expression of FPR and other chemokine
receptors at low nanomolar concentrations, but that the down-
regulation of FPR and the chemokine receptors was dependent
upon expression of CD4 [61]. Thus, there are a complicated set of
interactions between FPR and the receptors and co-receptors of
viruses, and FPR may play an important role in viral infections.
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